RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Immune Thrombocytopenia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review.
Dudley Matthew Z et al., Vaccine (24 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42691821/
- 2.
The risk of idiopathic thrombocytopenic purpura after first and second measles, mumps, rubella (MMR) vaccine doses in children born in England 2000-2019.
Andrews Nick et al., Vaccine (24 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42771940/
- 3.
CD19+ CD 38+ regulatory B lymphocytes as exploratory prognostic markers of steroid-induced remission in treatment-naïve adult immune thrombocytopenia.
Elbayoumi Noreen M et al., British journal of haematology (18 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893847/
- 4.
FAS and FASL expression in autoimmune lymphoproliferative syndrome and immune thrombocytopenia: limited diagnostic utility as transcriptional biomarkers.
Montanari Paola et al., Molecular biology reports (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886380/
- 5.
Severe Transfusion-refractory Cytopenia Mimicking Bone Marrow Failure in a Patient Living with HIV after Antiretroviral Therapy Interruption.
Okaya Shuichi et al., Internal medicine (Tokyo, Japan) (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41780986/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565 · Recruiting · Phase 2 · Incyte Corporation
Ages 18 and over
https://clinicaltrials.gov/study/NCT07104565
- 2.
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318 · Recruiting · Phase 3 · Takeda
Ages 18 and over
https://clinicaltrials.gov/study/NCT06948318
- 3.
OM336 in Autoimmune Cytopenias
NCT07083960 · Recruiting · Phase 1 · Lakefront Biotherapeutics West LLC
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07083960
- 4.
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235 · Recruiting · Phase 3 · Takeda
Ages 18 and over
https://clinicaltrials.gov/study/NCT06722235
- 5.
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417 · Recruiting · Phase 1 · Chugai Pharmaceutical
Ages 18 to 85
https://clinicaltrials.gov/study/NCT06371417
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Immune Thrombocytopenia
Immune Thrombocytopenia is an autoimmune disorder in which the immune system destroys platelets, causing low platelet counts and bleeding complications. It can occur at any age and may be acute (common in children) or chronic (more common in adults). Treatment ranges from watchful waiting to corticosteroids, intravenous immunoglobulin, and thrombopoietin receptor agonists.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: The Brighton Collaboration published its standard harmonized case definition for thrombocytopenia in 2007 to facilitate collection of valid and reproducible vaccine safety evidence and enable valid comparisons across studies. A companion guide to this case definition (including background incidence, risk factors, evidence for or against an association with vaccination, medical codes, data collection forms, and algorithms to support level of diagnostic certainty assessment) was initially published in 2021 and updated in 2025 based on a formal scoping review. This article reports the results of this scoping review, summarizing current evidence regarding the background incidence of and risk factors for thrombocytopenia, including immune thrombocytopenia (ITP) and its potential association with vaccination. METHODS: Two PubMed searches were conducted in July 2024: one for background incidence and non-vaccine risk factors, and one for vaccine associations. Search results were screened and relevant data were extracted and added to the corresponding companion guide tables. FINDINGS: Twenty-two articles contributed to the updated summary of background incidence, 36 articles contributed to the updated summary of non-vaccine risk factors, and 93 articles contributed to the updated summary of vaccine associations. Estimates of the background incidence of thrombocytopenia range between 1.6 and 92.1 per 100,000 person-years, depending on the study, region, and age range. Non-vaccine risk factors for thrombocytopenia include age, sex, genetics, season, geography, comorbidities, iatrogenesis, infection, medication, and food. While studies have consistently found an increased risk of ITP with measles-containing vaccines, and multiple studies found an increased risk following adenoviral COVID-19 vaccination, studies of other vaccines (including mRNA and inactivated COVID-19 vaccines) have largely found no association. CONCLUSION: Though rare, thrombocytopenia has many risk factors, including vaccination against measles. This review should be useful to stakeholders attempting to assess the occurrence of thrombocytopenia across a variety of settings, including as an adverse event following immunization.
Common Questions
What is Immune Thrombocytopenia?
Immune Thrombocytopenia is an autoimmune disorder in which the immune system destroys platelets, causing low platelet counts and bleeding complications. It can occur at any age and may be acute (common in children) or chronic (more common in adults). Treatment ranges from watchful waiting to corticosteroids, intravenous immunoglobulin, and thrombopoietin receptor agonists.
How many clinical trials are available for Immune Thrombocytopenia?
RareWays currently indexes 385 clinical trials for Immune Thrombocytopenia, of which 74 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Immune Thrombocytopenia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Immune Thrombocytopenia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.